Lupin enters into BTA with Lupin Manufacturing Solutions
Lupin enters into BTA with Lupin Manufacturing Solutions
Lupin enters into BTA with Lupin Manufacturing Solutions
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
The launch of Elores in Ecuador is expected to open the doors for the entry of the novel antibiotic adjuvant entity in other important Latin American countries
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
Lokavant provides clinical trial intelligence
This integrated care offering is a step forward in our vision of providing an effective continuum of care for patients
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
His M&A background and experience with successful private-equity-backed companies will benefit the company’s growth and diversification strategy
Glenmark will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to commercialize Winlevi in 15 EU countries
Subscribe To Our Newsletter & Stay Updated